Canadian Patents Database / Patent 2492434 Summary

Third-party information liability

Some of the information on this Web page has been provided by external sources. The Government of Canada is not responsible for the accuracy, reliability or currency of the information supplied by external sources. Users wishing to rely upon this information should consult directly with the source of the information. Content provided by external sources is not subject to official languages, privacy and accessibility requirements.

Claims and Abstract availability

Any discrepancies in the text and image of the Claims and Abstract are due to differing posting times. Text of the Claims and Abstract are posted:

  • At the time the application is open to public inspection;
  • At the time of issue of the patent (grant).
(12) Patent Application: (11) CA 2492434
(54) English Title: METHOD OF ENHANCING AND/OR INDUCING NEURONAL MIGRATION USING ERYTHROPOIETIN
(54) French Title: PROCEDE PERMETTANT D'ACCROITRE ET/OU D'INDUIRE UNE MIGRATION NEURONALE AU MOYEN DE L'ERYTHROPOIETINE
(51) International Patent Classification (IPC):
  • A61K 38/18 (2006.01)
  • A61K 38/22 (2006.01)
(72) Inventors (Country):
  • SHINGO, TETSURO (Japan)
  • ANDERSEN, LINDA B. (Canada)
  • WEISS, SAMUEL (Canada)
(73) Owners (Country):
  • STEM CELL THERAPEUTICS INC. (Canada)
(71) Applicants (Country):
  • STEM CELL THERAPEUTICS INC. (Canada)
(74) Agent: MARKS & CLERK
(45) Issued:
(86) PCT Filing Date: 2003-07-31
(87) PCT Publication Date: 2004-02-05
Examination requested: 2008-06-03
(30) Availability of licence: N/A
(30) Language of filing: English

(30) Application Priority Data:
Application No. Country Date
60/399,395 United States of America 2002-07-31

English Abstract




Methods are described for the enhancement and/or induction of migration of
neural stem cells or neuronal progenitor cells. Multipotent neural stem cells
are exposed to erythropoietin which enhances the migration of multipotent
neural stem cells and neuronal progenitor cells. The erythropoietin may be
exogenously applied to the multipotent neural stem cells, or alternatively,
the cells can be subjected to hypoxic insult which induces the cells to
express erythropoietin. In a preferred embodiment, additional growth factors,
such as EGF and prolactin, are utilized.


French Abstract

L'invention concerne des procédés permettant d'accroître et/ou d'induire une migration de cellules souches neurales ou de cellules progénitrices neuronales. Des cellules souches neurales multipotentes sont exposées à l'érythropoiétine accroissant la migration desdites cellules et des cellules progénitrices neuronales. L'érythropoiétine peut être appliquée de manière exogène sur les cellules souches neurales multipotentes ou, de manière alternative, les cellules peuvent être soumises à une agression hypoxique induisant l'expression de l'érythropoiétine par les cellules. Dans un mode de réalisation préféré, des facteurs de croissance supplémentaires, tels que le facteur de croissance de l'épiderme (EGF) et la prolactine, sont utilisés.


Note: Claims are shown in the official language in which they were submitted.


CLAIMS


We claim:

1. A method of enhancing multipotent neural stem cell and/or multipotent
neural stem cell progeny migration in a subject comprising administering an
erythropoietin
and at least one other growth factor to a subject in an amount effective to
enhance
migration of multipotent neural stem cells and/or multipotent neural stem cell
progeny.
2. The method of Claim 1, wherein the at least one other growth factor is
epidermal growth factor (EGF).
3. The method of Claim 2, wherein the EGF is EGF51N or EGF51Q.
4. The method of Claim 1, wherein the at least one other growth factor is
prolactin.
5. The method of Claim 1, wherein the erythropoietin is administered
concurrently with the at least one other growth factor.
6. The method of Claim 1, wherein the erythropoietin is administered
sequentially with the at least one other growth factor.
7. The method of Claim 1, wherein the at least one other growth factor is
administered prior to the erythropoietin.
8. The method of Claim 1, wherein the at least one other growth factor is
administered after the erythropoietin.
9. The method of Claim 1, wherein said subject is suffering from a
neurodegenerative disease or brain injury.



-23-


10. The method of Claim 9, wherein the subject is suffering from stroke.
11. The method of Claim 1, wherein the multipotent neural stem cells and/or
multipotent neural stem cell progeny migrate to the basal ganglia.
12. The method of Claim 1, 9, or 10, wherein the multipotent neural stem cells
and/or multipotent neural stem cell progeny migrate towards a lesioned or
damaged area
of the brain of the subject.
13. The method of Claim 1, wherein said subject is a human.
14. The method of Claim 1, wherein the multipotent neural stem cells and/or
progenitor cells which are derived from said multipotent neural stem cells are
transplanted
into said subject.
15. The method of Claim 14, wherein said multipotent neural stem cells and/or
progenitor cells are incubated with the erythropoietin and at least one other
growth factor
before being transplanted into said subject.
16. A method of inducing the migration of multipotent neural stem cells and/or
multipotent stem cell progeny comprising exogenously adding to said
multipotent neural
stem cells and/or multipotent neural stem cell progeny an amount of an
erythropoietin and
at least one other growth factor effective to cause the migration of
multipotent neural stem
cells and/or multipotent neural stem cell progeny.
17. The method of Claim 16, wherein the at least one other growth factor is
epidermal growth factor (EGF).
18. The method of Claim 17, wherein the EGF is EGF51N or EGF51Q.
19. The method of Claim 16, wherein the at least one other growth factor is
prolactin.



-24-


20. The method of Claim 16, wherein the erythropoietin is added concurrently
with the at least one other growth factor.
21. The method of Claim 16, wherein the erythropoietin is added sequentially
with the at least one other growth factor.
22. The method of Claim 16, wherein the at least one other growth factor is
added prior to the addition of the erythropoietin.
23. The method of Claim 16, wherein the at least one other growth factor is
added after the addition of the erythropoietin.
24. A method for inducing migration of multipotent neural stem cells and/or
multipotent neural stem cell progeny, comprising exposing said multipotent
neural stem
cells and/or multipotent neural stem cell progeny to hypoxic conditions to
induce
expression of erythropoietin and exogenously adding at least one other growth
factor in an
amount effective to induce migration.
25. The method of Claim 24, wherein said at least one other growth factor is
epidermal growth factor (EGF).
26. The method of Claim 25, wherein the EGF is EGF51N or EGF51Q.
27. The method of Claim 24, wherein the at least one other growth factor is
prolactin.
28. The method of Claim 24, wherein said at least one other growth factor is
added to said multipotent neural stem cells and/or multipotent neural stem
cell progeny
concurrently with hypoxic conditions.
29. The method of Claim 24, wherein said at least one other growth factor is
added to said multipotent neural stem cells and/or multipotent neural stem
cell progeny



-25-


sequentially with hypoxic conditions.
30. The method of Claim 24, wherein said at least one other growth factor is
added to said multipotent neural stem cells and/or multipotent neural stem
cell progeny
prior to exposure to hypoxic conditions.
31. The method of Claim 24, wherein said at least one other growth factor is
added to said multipotent neural stem cells and/or multipotent neural stem
cell progeny
after exposure to hypoxic conditions.



-26-


Sorry, the representative drawing for patent document number 2492434 was not found.

For a clearer understanding of the status of the application/patent presented on this page, the site Disclaimer , as well as the definitions for Patent , Administrative Status , Maintenance Fee  and Payment History  should be consulted.

Admin Status

Title Date
(86) PCT Filing Date 2003-07-31
(87) PCT Publication Date 2004-02-05
(85) National Entry 2005-01-13
Examination Requested 2008-06-03
Dead Application 2011-08-01

Payment History

Fee Type Anniversary Year Due Date Amount Paid Paid Date
Registration of Documents $100.00 2005-01-13
Registration of Documents $100.00 2005-01-13
Filing $400.00 2005-01-13
Maintenance Fee - Application - New Act 2 2005-08-01 $100.00 2005-01-13
Maintenance Fee - Application - New Act 3 2006-07-31 $100.00 2006-07-06
Maintenance Fee - Application - New Act 4 2007-07-31 $100.00 2007-07-09
Request for Examination $800.00 2008-06-03
Maintenance Fee - Application - New Act 5 2008-07-31 $200.00 2008-07-07
Reinstatement: Failure to Pay Application Maintenance Fees $200.00 2009-12-10
Maintenance Fee - Application - New Act 6 2009-07-31 $200.00 2009-12-10

To view selected files, please enter reCAPTCHA code :




Filter Download Selected in PDF format (Zip Archive)
Document
Description
Date
(yyyy-mm-dd)
Number of pages Size of Image (KB)
Abstract 2005-01-13 1 69
Claims 2005-01-13 4 125
Cover Page 2005-04-13 1 33
Description 2005-01-13 22 1,249
Drawings 2005-01-13 4 162
Prosecution-Amendment 2010-03-19 3 106
Prosecution-Amendment 2008-09-23 1 28
Prosecution-Amendment 2008-06-03 1 32